• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Cold Chain Packaging and Logistics

    How Artificial Intelligence and Machine Learning are Transforming the Life Sciences

    Challenges of Preparing Highly Potent Oral Products

    Bioprocessing Trends

    Sustainable Manufacturing
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    groninger Continues Growth in the US

    Catalent Bolsters Cell and Gene Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    What Does the Future of API Synthesis Look Like?

    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Jaguar Health Achieves Key Milestone for Crofelemer API Manufacturer
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Bolsters Cell and Gene Services

    CDMO Sirio Pharma Completes the Acquisition of Best Formulations

    Meeting the Container Closure Integrity Requirements in the Revised EU Annex 1

    Case Study: Secondary Sourcing Strategies to Ensure Supply Chain Security

    Beat the Supply Chain Backlog
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Catalent Bolsters Cell and Gene Services

    Crown Bioscience to Acquire Indivumed’s Service Biz and Supporting Biobank

    Stevanato Group, Transcoject Partner on Pre-Fillable Syringe Polymer Options
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Adare Partners with Veeva to Strengthen Quality Operations

    KBI Secures Swissmedic Regulatory Establishment License for Facility in Geneva

    Enhancing Ease of Use, Batch Turnaround, and Process Flexibility

    Understanding the Essential Role of a Qualified Person

    Altasciences Los Angeles Clinical Site Receives CAP Accreditation
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    INCOG BioPharma Services

    Chiron Recombinant Proteins

    Societal CDMO

    BioIVT

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    INCOG BioPharma Services

    Chiron Recombinant Proteins

    Societal CDMO

    BioIVT

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Getting PAT into Bioprocessing CMOs

    The Good, the Bad, and the “Whatever”

    Getting PAT into Bioprocessing CMOs
    Related CONTENT
    • Mogene
    • Softweb Solutions
    • Vetio Animal Health
    • Risk-Based Monitoring
    • The Orphan Promise
    Emil W. Ciurczak, DoraMaxx Consulting06.13.19
    Ever since I started doing near-infrared spectroscopy (NIRS), circa 1983, I have had an eye towards performing analyses in the warehouse and, later, in the process line. For decades, I had been performing “traditional” analyses: HPLC, GLC, TLC, polarography, thermal analysis, flame emission, UV/Vis, Mid-Range IR, etc. All are excellent methodologies, but all lab-based and used for AFTER-PRODUCTION analysis. These may be used to assure that an already finished product passes specifications, but, for all intents and purposes, cannot be used to control a process or tell where it may have gone OOS. Now, it appeared I had a tool that could be adapted to real-time analyses as is true for newer arrivals Raman and LIF, or light-induced fluorescence. My first use was in 100% qualification of all incoming raw materials (1984-5), but I needed to wait a few years for a chance to monitor a production process.

    In 1989, I suggested that any blending process (powder or liquid) could be followed by simply inserting a (NIR) probe, scanning at regular (short) intervals, and, when there are tiny or no further changes, the mixing process is complete. I was challenged by a manager at NIRSystems to “put up or shut up,” so I did the first blending study. I used a simple four-component system in a small vessel, rotating and stopping at regular intervals. Each time the “blender stopped,” I inserted a NIR probe at several depths and locations, repeating the procedure until the math (Principal Components) showed there to be no further changes. It was blended as well as possible. Clearly, later, wireless NIR units are true process tools, but we had to do some feasibility studies first.

    Then, a few years later, I got an opportunity to work on a process, in real time. In 1992, the plant engineer at Merck (West Point, PA) allowed me to chop a hole in the hopper of a production encapsulating machine and insert a NIR probe. I had been trying to monitor, with hopes of controlling, a solid dosage from production line. I was able to monitor the content uniformity of the granulation, enabling the process engineer to stop, should the content drop below a minimum or become enriched.

    In 2002, Ajaz Hussain convened a series of meetings/hearings and mini-conferences to present the technical capabilities and methodologies to monitor and control processes in real time. This led to the issuance of the PAT Guidance in 2004. The initial draft and subsequent final version were entirely based on small molecule, solid dosage forms. The U.S. FDA designed the PAT Guidance for small molecules for a number of good reasons:
    1. There is nearly zero chemistry involved (wetting and drying is hardly “real” chemistry), merely physical mixing. Any complex, chemical reactions all take place at the API synthesis step, at a different location, nearly always before the “process” of dosage form manufacture is performed.
    2. The use of in-line/at-line instrumentation is largely an extension of current laboratory equipment. Spectroscopy and physical methods are already familiar, only the need for faster sampling and analysis times, so operators/analysts have, at some level, have some familiarity with the newer equipment.
    3. The personnel roster of a small-molecule manufacturer includes more traditional chemists (organic, R&D, and QC) and numerous types of engineers, so the statistics/algorithms of process chemistry (multi-variate analyses) are not too foreign.
    4. Since the chemistry of the API was established prior to formulation of the dosage form, nearly all the production problems with solid dosage forms were embedded in the formulation, blending, and formation of the dosage forms: all physical and material issues.

    Another pragmatic reason was that the vast majority of marketed drugs (bulk sales = profits) were based on small molecules, while most biopharma companies were either new (start-ups) or still in the “R&D” stages, so there weren’t as many large molecule products in existence. But, as the big-money, super-drug supply line has dried a touch in recent years, there have been a few changes in the weather:
    1. The consequence of the “good old days” of blockbuster after blockbuster being introduced was the growth of large Pharma, largely through M&A (mergers and acquisitions). Larger facilities were great during growth periods, but, like licking one’s lips when chapped, it felt good, but, in the long run, was deleterious.
    2. The large overhead of maintaining huge “empires” (I believe, at the peak of growth, Pfizer had 82 sites), could not be maintained with “normal” sales of “merely” several hundred million in sales. Outsourcing was inevitable.
    3. With fewer small molecule NDEs (new drug entities), most of the big houses have been turning to macromolecules: i.e., biologics.

    What does this mean in terms of relationships with CMOs and CROs and their clients (sponsors)? Several things come to mind:
    1. Since most big houses are in the early stages of producing potential blockbusters (indeed, many are still in the R&D stage, with no marketed products), there is a paucity of contract companies capable of cranking out large numbers of biological products.
    2. In fact, few big BioPharma companies have true PAT and QbD in play. That makes it ever so difficult to “transfer” a PAT program to a contract site and, for that matter, generics with less available resources will have trouble implementing one.
    3. The vast majority of CMOs are set up to generate solid dosage forms, so many of them will be starting at zero, with a steep and high learning curve. Let alone having bio-personnel on staff.
    4. Even parts of big Pharma need intensive training to adapt PAT/QbD to their bioprocess lines.

    Now we can address the difficulties in beginning a (true) PAT/QbD program in both large and small companies. First, we need to assume that there is a staff on-site, familiar with the bioprocess (fermentation, clean-up, etc.), namely, biochemists, biologists, molecular biologists and chromatographers. That means that there is a paucity (as from above) of “traditional” personnel in the biopharma divisions/CMOs: analytical chemists, process engineers, material scientists, Chemometricians, etc.

    This means the actual training of biotech personnel will have to be modified. For companies rich in analytical chemists (R&D, development, and QC), pharmacists, and process engineers), an introductory course with some examples is sufficient. For a bioprocess site a different approach is needed:
    1. A deeper explanation of why each step needs to be monitored and controlled needs to be generated.
    2. Since there is little baseline information about the economics of this “newish” industry, merely using the “saves money” argument (as with tablet/capsule production) rings hollow. Many of these companies either do not make a profit/have a finished product or have one that is raking in money, such that savings are the last thing on their minds.
    3. Since biopharma companies are heavily weighted to life sciences, simply showing previous applications of PAT instruments will have less than full success. If no one in the audience/class has ever seen, let alone used a NIR, Raman, LIBS (LASER-induced breakdown spectroscopy), or LIF (light-induced fluorescence), merely showing some examples means little or nothing.
    4. All the FDA, EMA, and ICH Guidances mean little to a company/staff that has never (or seldom) been under Agency scrutiny, so these need to be placed in context; merely reading them will not suffice.
    5. Concepts such as QRM (quality risk management) and DoE (design of experiment) need more than simple explanations. The best approach, which I have done in Europe, is to choose (have them choose) a process/product as an example. What I did was make a series of PowerPoint slides, featuring their process. Shown as a block diagram, each step shows the chemistry (OK, “biology”), components, and potential monitor/control equipment, as well as software/algorithms used; and don’t forget to show how to validate each step.
    6. Stress and explain the personnel changes and training that will need to happen to generate a working PAT/QbD program:
    a. QA personnel will need (offsite?) training on, at a minimum, the ICH guidances: Q8 through Q11. They are both the conscience of the labs and production and the interface with the Agencies, so they need more than a “working knowledge” of the guidances.
    b. An enhanced IT department is a need. Granted, biological work requires a lot of statistics for clinical work and reaction overview, but multivariate analyses that will take place in a bioprocess PAT program will need people conversant with Chemometrics and process control algorithms.
    c. Hardware and an instrument group will need to be added. Process instrumentation is beyond the comfort zone of lab chemists (especially biochemists) and utterly foreign to the bioprocess people. Just calibration, maintaining, and repairing the hardware will be a new frontier for the company… and the current personnel will not likely be equipped (or emotionally prepared) to deal with utterly different hardware and technologies.
    d. AR&D and QC personnel, familiar with these newer technologies. They will need to find the technologies, specify the equipment, determine the location for them, when and how often to sample the process, how to model the data, and generate the equation to control a process.
    e. These same people will need to work  with the Chemometricians to maintain and update any multivariate equations being used to monitor and control the process. (And, don’t forget that need to explain the work to QA and the Agency.)

    So, in short, bringing a successful PAT/QbD program to biopharma is a horse of a different feather. It will be new and different, but very, very worthwhile. This will be a true case for the need of massive cooperation between the innovators and the contract manufacturers.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • Solid Dosage
    • biopharma companies
    • equipment
    • formulation
    Suggested For You
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Risk-Based Monitoring Risk-Based Monitoring
    The Orphan Promise The Orphan Promise
    Lilly Lilly's CYRAMZA Gains Fifth Indication
    The Coming Revolution of Personalized Medicine The Coming Revolution of Personalized Medicine
    Swissfillon Completes Successful FDA Inspection Swissfillon Completes Successful FDA Inspection
    Merck to Restructure Manufacturing Ops Merck to Restructure Manufacturing Ops
    Merck & NJII Receive NIIMBL Award Merck & NJII Receive NIIMBL Award
    Pharmaceutical Excipients Trends Pharmaceutical Excipients Trends
    The Unfolding Pharma Product Mix The Unfolding Pharma Product Mix
    KASA to Support Generic Drug Review KASA to Support Generic Drug Review
    PCI Bolsters Supply Chain Leadership PCI Bolsters Supply Chain Leadership
    Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

    Related Buyers Guide Companies

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • Softweb Solutions

      ...
      Micheal Jury, Marketing Manager 09.23.20

    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19


    • Risk-Based Monitoring

      Risk-Based Monitoring

      Leveraging intelligent analytics to realize the full value of RBx and compliance with ICH E6 (R2)
      Richard Davies, Vice President, Solution Expert, CluePoints 06.13.19

    • The Orphan Promise

      The Orphan Promise

      New policy on rare disease treatments likely soon
      S. Harachand, Contributing Editor 06.13.19

    Loading, Please Wait..
    Trending
    • Sarepta And Catalent Expand Manufacturing Partnership
    • Forge Biologics Strengthens Genetic Medicine CDMO Capabilities
    • Colorcon Signs Agreement To Purchase Airnov Healthcare Packaging
    • The Ongoing Evolution And Implementation Of DCTs In 2023
    • EyePoint Pharmaceuticals To Build GMP Mfg. Facility In Northbridge, MA
    Breaking News
    • Pasithea Signs CMC Development and Manufacturing Agreement
    • Experic Expands Analytical Capabilities and Facilities
    • List Labs Expands Manufacturing Capacity
    • groninger Continues Growth in the US
    • Catalent Bolsters Cell and Gene Services
    View Breaking News >
    CURRENT ISSUE

    November/December 2022

    • Cold Chain Packaging and Logistics
    • Optimizing Supply Chains for Allogeneic Cell Therapy Trials
    • Sustainable Manufacturing
    • Bioprocessing Trends
    • How Artificial Intelligence and Machine Learning are Transforming the Life Sciences
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Vitamin D Supplementation Reduces Risk of Dynapenia
    Sustained-Release Caffeine Ingredient Offers Mood, Performance Benefits
    Multi-Strain Probiotic Improves Self-Reported Mood, Sleep, Serotonin Levels
    Coatings World

    Latest Breaking News From Coatings World

    Epoxytec Announces New Website Launch
    Paints and Coatings Market Worth $212B by 2026: MarketsandMarkets
    Axalta Releases Fourth Quarter and Full Year 2022 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BMP Medical Expands Sterling, Massachusetts Facility
    Abbott's Proclaim XR SCS OK'ed for Diabetic Neuropathy
    Environmental Sustainability Becoming Increasingly Important to Medtech Industry
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pasithea Signs CMC Development and Manufacturing Agreement
    Experic Expands Analytical Capabilities and Facilities
    List Labs Expands Manufacturing Capacity
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Haircare Brand Uncle Funky’s Daughter Announces Retail Expansion
    TRESemmé Introduces New Pro Infusion Collection
    Walgreens Boots Alliance Shares 2022 ESG Report
    Happi

    Latest Breaking News From Happi

    KimChi Beauty Launches Spinning Hearts Love 02 Ahead of Valentine’s Day
    Dark & Lovely Names Actress Meagan Good Brand Ambassador
    Natural Household Care Company Tru Earth Adds Dishwasher Detergent Tablets
    Ink World

    Latest Breaking News From Ink World

    Xerox Releases 4Q, Full-Year 2022 Results
    Electronics For Imaging Names Frank Pennisi as CEO
    Fiery to Separate from EFI, Remain Wholly-Owned by Siris
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    EFI appoints Frank Pennisi CEO, Fiery now an independent business
    Bobst boosts senior sales team with Keith Nagle
    Penmar Industries adds Screen Truepress Jet L350UV SAI digital press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Essity’s Sales Grow
    Thinx to Pay up to $5 million to Settle Class Action Suit
    Typar Highlighting New Building Innovations
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthofix Launches the Mariner Deformity System
    Tyber Medical Hires 2 New Execs
    Miach Ortho Raises $40M in Series B Funding
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Smart Devices with Privacy Focus Have More Consumer Appeal
    Siman Group Partners with SML to Unlock Full Retail Potential with RFID
    Brewer Science Presents Optics Integration Solutions at SPIE Photonics West

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login